Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

Qing Zhou,Lin Wu,Luo Feng,Tongtong An,Ying Cheng,Jianying Zhou,Junling Li,Ji-feng Feng,Li Zhang,Baohui Han,Walson Xu,Lvyu Zhu,Li Xu,Xiao Xu,Feng Roger Luo,Yi-Long Wu

Safety and efficacy of abivertinib (AC0010), a third-generation EGFR tyrosine kinase inhibitor, in Chinese patients with EGFR-T790M positive non-small cell lung cancer (NCSLC).

2019

Qing Zhou
Lin Wu
Luo Feng
Tongtong An
Ying Cheng
Jianying Zhou
Junling Li
Ji-feng Feng
Li Zhang
Baohui Han
Walson Xu
Lvyu Zhu
Li Xu
Xiao Xu
Feng Roger Luo
Yi-Long Wu

9091Background: Abivertinib (AC0010) is a potent, selective third-generation EGFR tyrosine kinase inhibitor (TKI) that demonstrated clinical efficacy and manageable adverse events (AEs) in the phas...

Keywords:

Pathology
Cell
EGFR T790M
Tyrosine-kinase inhibitor
Cancer research
Adverse effect
Lung cancer
Medicine
third generation
non small cell
clinical efficacy
egfr tyrosine kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations